Keith D. Greenfield
Fondatore presso Dover Group, Inc.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| David R. Elmaleh | M | 76 |
NanoTomer, Inc.
 NanoTomer, Inc. Miscellaneous Commercial ServicesCommercial Services NanoTomer, Inc. provides bio technology services. The company is headquartered in Boston, MA.
AZTherapies, Inc.
 AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 13 anni |
| Gordana Vunjak-Novakovic | M | 75 |
Xylyx Bio, Inc.
 Xylyx Bio, Inc. Pharmaceuticals: MajorHealth Technology Xylyx Bio, Inc. provides drug discovery and development services for patients. The company is based in Brooklyn, NY. The company was founded in 2016 by Gordana Vunjak-Novakovic, John D. O'Neill. The CEO is Andrea Nye. | 8 anni |
| Renata Pasqualini | M | - |
PhageNova Bio, Inc.
 PhageNova Bio, Inc. BiotechnologyHealth Technology PhageNova Bio, Inc. is a biotechnology company that is developing a modular, bacteriophage-based platform for targeted gene expression in cancer, vaccination, and molecular imaging. PhageNova Bio is based in Scarsdale, NY. The company's lead cancer construct is designed to selectively target tumor-associated blood vessels and tumor cells, resulting in the expression of TNF-?, an anti-tumor agent, specifically and exclusively in tumors. The company has extensively validated tumor targeting and selective gene expression capabilities, and therapeutic efficacy was observed in the absence of dose-limiting toxicity in multiple species and several tumor models. The company was founded by Renata Pasqualini, Wadih Arap, Steven K. Libutti, Juri G. Gelovani, and the CEO is Jason A. Rifkin. | - |
| John D. O'Neill | M | - |
Xylyx Bio, Inc.
Xylyx Bio, Inc. Pharmaceuticals: MajorHealth Technology Xylyx Bio, Inc. provides drug discovery and development services for patients. The company is based in Brooklyn, NY. The company was founded in 2016 by Gordana Vunjak-Novakovic, John D. O'Neill. The CEO is Andrea Nye. | 8 anni |
| Andrea Nye | F | - |
Xylyx Bio, Inc.
Xylyx Bio, Inc. Pharmaceuticals: MajorHealth Technology Xylyx Bio, Inc. provides drug discovery and development services for patients. The company is based in Brooklyn, NY. The company was founded in 2016 by Gordana Vunjak-Novakovic, John D. O'Neill. The CEO is Andrea Nye. | - |
| Steven K. Libutti | M | - |
PhageNova Bio, Inc.
PhageNova Bio, Inc. BiotechnologyHealth Technology PhageNova Bio, Inc. is a biotechnology company that is developing a modular, bacteriophage-based platform for targeted gene expression in cancer, vaccination, and molecular imaging. PhageNova Bio is based in Scarsdale, NY. The company's lead cancer construct is designed to selectively target tumor-associated blood vessels and tumor cells, resulting in the expression of TNF-?, an anti-tumor agent, specifically and exclusively in tumors. The company has extensively validated tumor targeting and selective gene expression capabilities, and therapeutic efficacy was observed in the absence of dose-limiting toxicity in multiple species and several tumor models. The company was founded by Renata Pasqualini, Wadih Arap, Steven K. Libutti, Juri G. Gelovani, and the CEO is Jason A. Rifkin. | - |
| Jason Rifkin | M | 46 |
PhageNova Bio, Inc.
PhageNova Bio, Inc. BiotechnologyHealth Technology PhageNova Bio, Inc. is a biotechnology company that is developing a modular, bacteriophage-based platform for targeted gene expression in cancer, vaccination, and molecular imaging. PhageNova Bio is based in Scarsdale, NY. The company's lead cancer construct is designed to selectively target tumor-associated blood vessels and tumor cells, resulting in the expression of TNF-?, an anti-tumor agent, specifically and exclusively in tumors. The company has extensively validated tumor targeting and selective gene expression capabilities, and therapeutic efficacy was observed in the absence of dose-limiting toxicity in multiple species and several tumor models. The company was founded by Renata Pasqualini, Wadih Arap, Steven K. Libutti, Juri G. Gelovani, and the CEO is Jason A. Rifkin. | - |
| Peter S. Conti | M | 67 |
NanoTomer, Inc.
NanoTomer, Inc. Miscellaneous Commercial ServicesCommercial Services NanoTomer, Inc. provides bio technology services. The company is headquartered in Boston, MA.
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | - |
| Karen Reeves | M | - |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 7 anni |
| Donna See | F | - |
Xylyx Bio, Inc.
Xylyx Bio, Inc. Pharmaceuticals: MajorHealth Technology Xylyx Bio, Inc. provides drug discovery and development services for patients. The company is based in Brooklyn, NY. The company was founded in 2016 by Gordana Vunjak-Novakovic, John D. O'Neill. The CEO is Andrea Nye. | - |
| Matthew Bacchetta | M | - |
Xylyx Bio, Inc.
Xylyx Bio, Inc. Pharmaceuticals: MajorHealth Technology Xylyx Bio, Inc. provides drug discovery and development services for patients. The company is based in Brooklyn, NY. The company was founded in 2016 by Gordana Vunjak-Novakovic, John D. O'Neill. The CEO is Andrea Nye. | - |
| Brian Bartlett | M | - |
NanoTomer, Inc.
NanoTomer, Inc. Miscellaneous Commercial ServicesCommercial Services NanoTomer, Inc. provides bio technology services. The company is headquartered in Boston, MA. | - |
| Jeffrey Bell | M | - |
NanoTomer, Inc.
NanoTomer, Inc. Miscellaneous Commercial ServicesCommercial Services NanoTomer, Inc. provides bio technology services. The company is headquartered in Boston, MA. | - |
| Anthony A Curro | M | - |
Xylyx Bio, Inc.
Xylyx Bio, Inc. Pharmaceuticals: MajorHealth Technology Xylyx Bio, Inc. provides drug discovery and development services for patients. The company is based in Brooklyn, NY. The company was founded in 2016 by Gordana Vunjak-Novakovic, John D. O'Neill. The CEO is Andrea Nye. | - |
| Timothy Rothwell | M | 73 |
PhageNova Bio, Inc.
PhageNova Bio, Inc. BiotechnologyHealth Technology PhageNova Bio, Inc. is a biotechnology company that is developing a modular, bacteriophage-based platform for targeted gene expression in cancer, vaccination, and molecular imaging. PhageNova Bio is based in Scarsdale, NY. The company's lead cancer construct is designed to selectively target tumor-associated blood vessels and tumor cells, resulting in the expression of TNF-?, an anti-tumor agent, specifically and exclusively in tumors. The company has extensively validated tumor targeting and selective gene expression capabilities, and therapeutic efficacy was observed in the absence of dose-limiting toxicity in multiple species and several tumor models. The company was founded by Renata Pasqualini, Wadih Arap, Steven K. Libutti, Juri G. Gelovani, and the CEO is Jason A. Rifkin. | - |
| Ronald G. Tompkins | M | - |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | - |
| Gillian Sandler | F | - |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 6 anni |
| George D. Behrakis | M | - |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 5 anni |
| Noah Gottdiener | M | 67 |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 4 anni |
| Thierry Porté | M | 67 |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 4 anni |
| David Adams Taft | M | 67 |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | - |
| Steven Prelack | M | 66 |
Sight Code, Inc.
| - |
| John Robert Camber Porter | M | 71 |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | - |
| Tom Samodolski | M | - |
Dover Group, Inc.
| - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Marc M. P. de Garidel | M | 66 |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 1 anni |
| Jay Mohr | M | - |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 1 anni |
| Philip Ashton-Rickardt | M | 60 |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 2 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 27 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Keith D. Greenfield
- Contatti personali
